NIQ Unveils Groundbreaking AI Tools for CPG Brands at FastCompany Innovation Festival 2024 Providing Human-Powered Insights at the Speed of AI
16.9.2024 17:10:00 CEST | Business Wire | Press release
Introduces the world’s first CPG large language model and BASES AI, a tool using real consumer-permissioned data to create synthetic panels for concept testingNew language model boasts 7x the automation of public models, identifying, organizing, and categorizing products trained on 160 petabytes of dataBASES AI produces synthetic survey panels that test and benchmark ideas at a fraction of the cost and time
NielsenIQ (NIQ), the world’s leading global consumer intelligence company, announced two breakthroughs in artificial intelligence that further validate its leadership position. BASES AI and the CPG industry’s first large language model will help NIQ clients harness the power of responsible AI to drive innovation and grow market share. NIQ will also be speaking about AI trends in consumer buying intelligence and innovation at a panel on Thursday, September 19th at 2:20pm ET titled “Does AI Know What We Truly Want? How Synthetic Respondents Are Disrupting Product Innovation.”
BASES AI is a platform that uses consumer-permissioned data on consumption patterns across hundreds of thousands of households to mimic consumer behavior. The platform has access to data in real time, allowing it to create large panels of synthetic respondents to replicate trusted market research techniques and methodologies in a fraction of the time. Instead of days or weeks to gather human feedback, BASES AI can provide concept potential analysis in as little as 10 minutes. CPG companies can use these scores, as well as rich guidance on drivers of interest and uniqueness, to iterate on ideas ahead of final qualification with human consumers. The speed and quality of BASES AI means a larger volume of ideas can be evaluated while reducing overall innovation timelines. The release of BASES AI to Beta-testers in North America is coupled with the release of NIQ’s first CPG-specific language model, powering the advanced product segmentation capabilities of NIQ’s flagship Discover retail measurement platform. By leveraging NIQ’s database of 160 million products, the model outperforms public LLM models by over 7x in its ability to quickly and accurately code items. With access to new accelerators, the model will continue to evolve in both capability and sophistication, providing our clients with the Full View™ of their market and consumers through unparalleled insights.
“As the leading consumer intelligence player, we unlock mission-critical insights,” said Ramon Melgarejo,President, Strategic Analytics & Insights at NIQ. “In a fast-moving, consumer market focused on trend-based innovation, high-quality data is essential, and the ability to harness and extract insights from it will make all the difference in the world. These releases are the latest examples of how we are deploying our analytic horsepower across market-leading data sets to generate unparalleled insights that help CPG companies gain market share globally.”
NIQ’s world-class product suite brings the power of 2,000 engineers focused on analyzing $7.2 trillion in annual global consumer spending and data from more than 3,200 unique retailer partnerships. With an extensive set of data sources spanning multiple countries and thousands of data scientists focused on developing responsible AI-driven business intelligence solutions, NIQ remains the market leader in creating, maintaining, and driving new market share for clients.
BASES AI and NIQ’s CPG language model are the latest AI-powered solutions among NIQ’s vast existing product set. The company recently announced the integration of Consumer Panel and Retail measurement data on the NIQ Discover Platform, transforming the consumer insights landscape through advanced analytical models and always-on capabilities that deliver customizable client insights in response to their mission-critical queries. This cloud-based platform is one of several recent product enhancements including Microsoft Azure Marketplace integration; Tik Tok Shop collaboration; and NIQ Spaceman services for SPAR International partners globally. All of these announcements come on the heels of the company’s generative AI tool with global search, personalized data analysis, and recommendations for informed decision making, NIQ Ask Arthur, launched earlier this year.
“The drive to innovate and excel has been coded into NIQ’s DNA for over a century,” added Mohit Kapoor, Chief Technology Officer at NIQ. “Our completed integration of GfK creates a company with roughly 25,000 clients, regularly analyzing 2.48 trillion transactions a week. NIQ’s unique ability to offer the Full View™ – the world’s most complete and clear view of consumer buying behavior with AI-powered predictive analytics – allows us to experiment with an even larger number of parameters, uniquely positioning us to capture the market opportunity for the next 100 years.”
NIQ also regularly provides unique, proprietary insights across global consumer trends, including its latest SpendZ report, a comprehensive look at the spending trends of Gen Z and regular Consumer Outlook reports analyzing trends, behavior, and sentiment.
About NIQ
NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
For more information, please visit www.niq.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916757530/en/
Contacts
Media:
Media:
Sweta Patra
sweta.patra@nielseniq.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom